Longitudinal quality of life analysis in a phenylketonuria cohort provided sapropterin dihydrochloride

Teresa D Douglas1,2, Usha Ramakrishnan3, Julie A Kable4,5 and Rani H Singh1*

Abstract

Background: Sapropterin dihydrochloride effectively lowers plasma phenylalanine (Phe) for at least a third of phenylketonuria (PKU) patients, with potential for increased dietary Phe tolerance and decreased medical food requirement.

Objective: To investigate long-term quality of life (QOL) in patients with phenylketonuria (PKU) who took sapropterin (BH4, Kuvan®) for up to one year.

Methods: 37 PKU patients, ages 10–49 years, were asked to complete a PKU-specific self-report QOL questionnaire (QOLQ) at baseline, 1, 4, 8, and 12 months. Questions were scored on a 5-point Likert scale under 5 sub-sections measuring Impact, Worries, Satisfaction, Support, and General wellbeing in relation to PKU. Responders with a plasma Phe decrease ≥15% after 1 month on sapropterin remained on the drug; Nonresponders ceased sapropterin after the trial month. Responders able to relax medical diet and maintain plasma Phe control were classified as Definitive; Responders unable to relax medical diet were classified as Provisional. All patients were routinely monitored by a registered dietitian. Data was analyzed in SPSS 19.0 using regression techniques.

Results: Of 17 Responders, 11 could maintain adequate Phe control on a less restrictive diet. One year mean Impact sub-score trends improved significantly for all sapropterin response groups, with greatest improvement among Definitive Responders (p < 0.0001). Satisfaction sub-scores also improved for Definitive Responders (p = 0.001). Trends for Total QOL score improved significantly over time for both Definitive (p = 0.001) and Provisional Responders (p = 0.028). Improvements in Definitive Responder scores were associated with increased Phe tolerance (Impact: p < 0.0001, Satisfaction: p = 0.022, Total QOL: p = 0.005) and MF adjustment (Satisfaction: p = 0.014, Total QOL: p = 0.026). Other sub-section scores remained steady, unaffected by sapropterin response or diet modification.

Conclusion: Increased Phe tolerance and reduced MF requirement in sapropterin Definitive Responders improves QOL perception across one year, specifically for life impact and satisfaction.

Keywords: Phenylketonuria, PKU, Quality of life, Sapropterin, Tetrahydrobiopterin, BH4, Medical diet

Background

 Phenylketonuria (PKU) is a recessively inherited inborn error of metabolism. Impaired phenylalanine hydroxylase (PAH) activity in PKU inhibits the effective metabolism of its phenylalanine (Phe) substrate. Blood Phe concentrations can therefore increase to neurotoxic concentrations. Since Phe is ubiquitously found in most food sources, to prevent neurologic damage induced by high Phe concentrations, those with PKU must follow a strict low Phe diet throughout their lives and consume a Phe-free amino acid rich medical food as their primary source of protein nutrition. This diet treatment strategy involves daily monitoring of medical food and Phe intake so that patients with PKU can maintain plasma Phe concentrations within the safe therapeutic threshold of 100–360 μmoles/L.

 Although newborn screening has enabled dietary treatment for PKU to begin during early infancy, thereby
avoiding neurologic consequences such as severe lifelong developmental and cognitive disability, the dietary regimen for PKU can be rigorous, expensive, and socially burdensome to both families and patients [1,2]. In particular, patients transitioning into adolescence and adulthood will demonstrate decreased dietary compliance and plasma Phe concentrations increased beyond the therapeutic range [3,4]. Although the consequences are not as severe as during infancy and young childhood, this non-compliance has been shown to lead to neurological sequelae such as increased risk of mood disorders [5], attention deficits [6,7], impairments to executive functioning [8-10], school performance and achievement [11], and social difficulties [12], issues which can certainly impact QOL. Past studies have implicated both high plasma Phe concentrations as well as the strict medical diet in reduced quality of life (QOL) for patients with PKU [13,14].

Sapropterin dihydrochloride, a pharmaceutical form of the chaperone PAH cofactor tetrahydrobiopterin (BH4), not only lowers plasma Phe concentrations for up to half of patients with PKU [15], but many of these sapropterin responders are reported to also experience notable increases in dietary Phe tolerance, allowing for a less restricted diet as long as they remain on the pharmaceutical [16]. This study is the first to evaluate QOL in a combined adolescent and adult cohort of patients with PKU for one year after initiating sapropterin. Our objective was to determine if decreased plasma Phe and increased dietary Phe tolerance induced by sapropterin would improve self-reported QOL in adolescent and adult patients with PKU.

Methods
Study design and patient enrollment
Patients 10 years of age and older with PKU who planned to start sapropterin dihydrochloride (Kuvan, BioMarin Pharmaceutical Inc.) were asked to volunteer for a 1 year prospective cohort study in which QOL would be evaluated in the form of a self-report questionnaire. All patients were recruited through the Emory University Genetics Clinic in Atlanta Georgia. Enrollment lasted from October 2008 through October 2009. Participants were asked to complete the questionnaire prior to starting sapropterin as well as at 1, 4, 8, and 12 months thereafter. Blood was collected during corresponding clinic visits for evaluation of plasma amino acids (PAA) (Biochrom 30 HPLC Amino Acid Analyzer) (μmoles/L). Three day food records were collected and analyzed by a licensed registered dietitian. Food records were analyzed using Nutrition Data System for Research (NDSR) to calculate average daily intake of energy (kcal), Phe (mg), and protein (g). Reported intake of medical food protein and dietary Phe was assessed in parallel with the patients’ medical food protein prescription (g/day) and dietary Phe tolerance (mg/day), with the dietitian adjusting as needed.

Preliminary response to sapropterin was determined after one month of taking 20 mg/kg/day of the medication. Patients were instructed to continue with current medical food and dietary Phe practices to ensure that observed changes in plasma Phe were due to sapropterin response rather than dietary manipulation. Patients were classified as Preliminary Responders if plasma Phe decreased by at least 15% and continued on sapropterin throughout follow-up. Patients without this decline in plasma Phe were classified as Non-responders and discontinued the medication. All patients met with a registered dietitian during clinic visits. Non-responders were encouraged to continue with their prescription diet plan, while Preliminary Responders were provided Phe challenge and assessed for decreased medical food requirement. In agreement with criteria published by Singh and Quirck [16], Preliminary Responders who could maintain plasma Phe below the 360 μmol/L therapeutic threshold while increasing Phe tolerance and decreasing medical food intake were determined to be Definitive whereas Provisional Responders could not increase Phe or lower medical food without compromising plasma Phe.

Patients provided written informed consent, or the legal guardian’s written informed consent with age appropriate patient verbal or written assent, prior to study participation. Study protocol and informed consent procedures were approved by the Emory University institutional review board (IRB). Inclusion criteria were a diagnosis of PKU, minimum age of 10 years, and intent to begin sapropterin as a treatment for PKU. Exclusion criteria were having had bipterin therapy within 8 weeks prior to study involvement, pregnancy or planning to become pregnant, and literacy or comprehension difficulties that would limit patient ability to provide informed consent or complete the QOL questionnaire.

Quality of life questionnaire
The QOL questionnaire selected for this investigation, the PKU-QOLQ, was developed to evaluate QOL parameters specific to the experience of living with PKU. The PKU-QOLQ is patterned after the validated juvenile diabetes QOL questionnaire [17] and has been shown to predict positive adaptive outcome in a cohort of adolescent females with PKU [18]. The adapted PKU-QOLQ consists of five quantitative subsections, each with a subset of numbered questions that can be answered on a five-point Likert scale (subsections and scoring ranges are described in Table 1). Subsections evaluated 5 areas in which PKU could influence quality of life: impact of PKU on life quality, PKU related life worries, satisfaction with life and medical management, sense of support from social network and clinical community, and perspective on general well-being.
For Impact and Worries, 1–5 choices were “all the time, often, sometimes, very seldom, and never”. For Satisfaction and General sections, 1–5 Likert scale choices were “very unsatisfied, somewhat unsatisfied, neither, somewhat satisfied, very satisfied”. Subscores for the quantitative subsections were combined into a total QOL score.

Statistical analysis
Study sample size was determined a-priori using SPSS SamplePower 2.0 software. SamplePower’s sample size and power analysis technique utilize Cohen’s calculations for determining effect size and study power [19]. For this investigation, an effect size of 1.22 was calculated from an $r^2$ value of 0.55 found in a 2008 paper which showed association between diet related plasma Phe improvements and quality of life in PKU patients [13]. Thus, for this study, a minimum sample size of 18 was determined to be sufficient for a power of 0.8 with $\alpha = 0.05$, and a maximum of 5 covariates in linear models.

Statistical analysis of final data was completed using SPSS 19.0. Baseline analysis of variable associations with QOL scores utilized Pearson correlation and multivariate linear regression. Cox regression survival analysis was used to investigate the impact of baseline variables on attrition. ANCOVA by generalized linear method was used for analysis across groups between baseline and one month. Mixed linear regression using an unstructured variance-covariance type model was used to evaluate trends across one year of follow-up since the method is robust in circumstances of unbalanced longitudinal data [20]. When relevant, mixed models were adjusted for significant variation in intercepts or slopes. Variables evaluated for association with QOL outcomes include age, gender, physical activity level (scored on a 1–5 Likert scale of low to high physical activity), income, education, family marital status, prescribed medical food protein, dietary Phe tolerance, plasma amino acids, and sapropterin response. All analyses were two-tailed with $\alpha = 0.05$.

Results
Demographics, sapropterin response, and attrition
Thirty-seven male and female patients, age 10–49 years (mean ± SD: 22.1 ± 9.4) enrolled in the study. Baseline demographic data is portrayed in Table 2. At one month, 36 patients returned, with 17 classified as preliminary Responders and 19 as Non-responders. Of the preliminary Responders, Phe challenge revealed 11 to be Definitive and 6 to be Provisional by the study’s fourth month. Seven of the Non-responders were lost to follow-up before the study year was complete. Support sub-scores at baseline, but no other QOL outcomes, had a positive correlation with length of time Non-responders remained in the study ($r = 0.45$, $p = 0.005$). Single marital status was also associated with higher attrition in Non-responders ($p = 0.037$). Plasma Phe, dietary Phe, medical food intake, age, gender, income, and education level were not associated with attrition. Of the 29 patients who completed the long-term QOL study, 8 failed to return the PKU-QOLQ one or more times during the study while 2 others did not complete all subsections of the PKU-QOLQ on one or more occasions.

QOL at baseline
Table 1 describes the average QOL scores, and scoring ranges, for the PKU cohort at baseline. Total and sub-scores averaged high, with at least 74% of participants having baseline sub-scores above the mid-score and 94% having a total QOL score above mid-score.

Total QOL score and all sub-scores other than Support sub-score were inversely correlated with age (Table 3); associations with QOL scores, except for Support sub-score, are therefore age adjusted. Plasma tyrosine was inversely associated with Worries sub-score ($p = 0.025$) at baseline but with no other QOL scores. Self reported physical activity level had a positive correlation with General well-being sub-score ($p = 0.018$), while patients diagnosed with one or more psychiatric disorders (ie: depression, anxiety, bipolar disorder) reported lower Satisfaction scores ($p = 0.028$) (Figure 1). Plasma Phe, prescribed diet, marital status,
income and education level were not associated with baseline QOL scores. There were also no differences in baseline PKU-QOL scores among prospective sapropterin response groups. Controlling for same-household siblings did not affect results.

QOL after 1 month of sapropterin
Characteristic of preliminary response to sapropterin, plasma Phe significantly dropped ($p = 0.008$) after the first month for 47% of study patients (Figure 2). However, no statistically significant change in PKU-QOL scores occurred within or between Responders and Non-responders from baseline to 1 month, even when controlling for later determined Definitive and Provisional response classification.

QOL during 1 year
Baseline associations of age and physical activity with QOL scores were unaltered in the long-term analysis and were thus controlled for in relevant mixed regression models. Although plasma tyrosine was inversely associated with Worries sub-scores at baseline, the association was not significant long-term regardless of sapropterin response classification. The impact of psychiatric or ADHD status on long-term QOL outcomes could not be determined due to the attrition within those smaller categories.

There were no statistically significant differences between sapropterin response groups in PKU-QOL scores during 1 year of follow-up, however significant within group changes did occur. All response groups demonstrated a trend towards improved Impact sub-scores, with Definitive Responders experiencing the greatest improvement ($p < 0.0001$) compared to Provisional Responders ($p = 0.01$) and Non-responders ($p = 0.05$) (Figure 3B). Trends for Satisfaction sub-scores increased significantly for Definitive Responders only ($p = 0.001$) (Figure 3A), while Worries, Support, and General well-being sub-scores did not change significantly, irrespective of sapropterin response. Trends in Total QOL scores significantly improved for both Definitive ($p = 0.001$) and Provisional Responders ($p = 0.028$) (Figure 3C). Although Non-responders experienced a modest improved trend in Impact sub-scores, total

### Table 2 Baseline demographics of study participants (N = 37)

| Variable                      | N (%)       |
|-------------------------------|-------------|
| Gender                        |             |
| Male                          | 20 (54%)    |
| Female                        | 17 (46%)    |
| Age (years)                   |             |
| Adolescent (10–19)            | 19 (51%)    |
| Adult (20+)                   | 18 (49%)    |
| 3 pairs of biological siblings| 6 (16%)     |
| Neuropsychiatric and Behavioral diagnoses |          |
| No diagnosis                  | 29 (78%)    |
| ADHD                          | 4 (11%)     |
| Other (Depression, Bipolar, Anxiety) | 4 (11%)    |
| Family marital status‡        |             |
| Single                        | 7 (19%)     |
| Married                       | 26 (70%)    |
| Divorced                      | 3 (8%)      |
| Widowed                       | 1 (3%)      |

‡Marital status represents participants themselves age 19+, and of the legal guardians for patients <19 years.

### Table 3 Baseline age-adjusted correlations of PKU-QOL scores

|                         | Impact | Worries | Satisfaction | Support | Generally | Total score |
|-------------------------|--------|---------|--------------|---------|-----------|-------------|
| Age (years)             | -37*   | -35*    | -48**        | NS      | -55**     | -58***      |
|                         | (-.63, -04) | (-.61, -.02) | (-.70, -.17) | (-.75, -.26) | (-.77, -.30) |
| Plasma Phe (μmoles/L)   | NS     | NS      | NS           | NS      | NS        | NS          |
| Plasma Tyrosine (μmoles/L) | NS     | NS      | NS           | NS      | NS        | NS          |
|                         | (?07, .64)       |          |              |         |           |             |
| Phe tolerance (mg/day)  | NS     | NS      | NS           | NS      | NS        | NS          |
| MF protein Rx (g/day)   | NS     | NS      | NS           | NS      | NS        | NS          |
| Physical activity       | NS     | NS      | NS           | NS      | NS        | NS          |
|                         | (?08, .66)       |          |              |         |           |             |
| Psych/Behavior diagnosis| NS     | NS      | -38*         | NS      | NS        | NS          |
|                         | (-.63, -.05)     |          |              |         |           |             |

Pearson coefficient (95% CI).

* = $p < .05$, ** = $p < .01$, *** = $p < .001$.  
CI = Confidence Interval, Rx = Prescription, MF = Medical food.  
NS = Not statistically significant.  
‡: Psychological and behavior diagnosis dummy coded in SPSS: 1 = no diagnosis, 2 = ADHD diagnosis, 3 = psychiatric diagnosis (Bipolar, Depression, Anxiety).
QOL scores for Non-responders did not change significantly over one year.

**Association of plasma Phe, Phe tolerance, and prescribed medical food with long-term QOL scores**

Table 4 details the significance of regressed associations between long-term QOL scores and the modifiers plasma Phe, dietary Phe tolerance, and prescribed medical food protein.

Significant long-term declines in plasma Phe among Definitive Responders ($p = 0.002$) (Figure 2) was associated with linear increases to Satisfaction ($p < 0.0001$), Impact ($p = 0.002$), and total QOL scores ($p = 0.001$).

Interestingly, plasma Phe had a direct association with Impact sub-scores in Non-responders ($p = 0.038$), though was not associated with Provisional Responder’s QOL scores.

Observed increases to dietary Phe tolerance inherent to Definitive Responder status (Figure 4A) were associated with improved trends in Impact ($p < 0.0001$), Satisfaction ($p = 0.025$), and Total ($p = 0.005$) QOL scores across one year. Phe tolerance, remaining unchanged for Provisionals and Non-responders, had a significant positive association with Impact subscores for Non-responders ($p = 0.012$), although not for Provisionals ($p = 0.062$).

Significant reductions to prescribed medical food protein (g/day) for Definitive Responders (Baseline Mean ± SD: 51.8 ± 20.8, 1 year: 9.0 ± 12.5) ($p < 0.0001$) (Figure 4B) accommodated increases to protein and energy intake from intact food sources within the limits of effective Phe control. Reductions to medical food Rx in Definitive Responders was associated with better Satisfaction sub-scores ($p = 0.014$) and total QOL score ($p = 0.026$). For the undifferentiated PKU cohort, higher Impact scores had a long-term linear association with lower medical food prescriptions ($p = 0.04$), but the association was not maintained once stratified by sapropterin response groups. No other QOL scores were influenced by medical food prescription long-term, irrespective of sapropterin response.

**Discussion and conclusion**

The observation that most of our study patients had QOL scores exceeding the mid-score, with high means at both baseline and throughout the study (Table 1, Figures 3A-C), is consistent with other research demonstrating good QOL in adults, adolescents, and young children with PKU when compared to non-PKU reference samples [12,21-23], although Cotungo’s 2011 study did discover lower parent reported QOL scores for children with PKU compared to a non-PKU reference group [21]. Since the focus of our study was to investigate sapropterin’s influence, along with relevant dietary modifications, on self-reported QOL within a cohort living with PKU, as opposed to comparing QOL in PKU to that of non-PKU populations, our results do not conflict with the Cotungo’s 2011 pediatric results. The high baseline scores of our study patients, however, may create a ceiling effect that inhibits observation of long-term changes; in essence, improvements to quality of life may not be as measurable when quality of life is already near the upper scale limits. This phenomenon may be a reflection of patient adaptation, in an emotional and psychological sense, to their disorder [24,25] or it may indicate a need for improved sensitivity in the questionnaire’s QOL scale. In addition, 83% of the cohort reported Phe intake above Phe tolerance at baseline (Figure 5); thus, improvements...
to QOL extending from sapropterin induced increases to Phe tolerance could be attenuated in patients already consuming liberal amounts of dietary Phe. This may explain the lack of observed change in the PKU-QOL sub-scores for Worries, Support, and General well-being.

Even so, we were able to detect improvements in Impact, Satisfaction, and Total QOL outcomes across one year in our patient sample, most pronounced in those PKU patients on sapropterin able to liberalize diet. This may seem contrary to Ziesch’s study where no changes in health related QOL were observed after 3 months in pediatric patients with PKU provided sapropterin, irrespective of ability to liberalize diet while maintaining good blood Phe control. However, our analysis of a larger adolescent & adult cohort evaluated QOL multiple times across a full year, allowing us to observe the gradual long-term positive
differences.

Table 4 Variable interactions‡ with QOL scores across time for sapropterin response groups and whole study sample †

|                      | Impact                  | Satisfaction          | Total score             |
|----------------------|-------------------------|-----------------------|-------------------------|
|                      | D | N | P       | All       | D | N | P   | All      | D | N | P   | All      |
| Phe tolerance (mg/day) | (+)*** | (+)* | N5 | (+)***           | (+)* | N5 | N5   | (+)*       | (+)** | N5 | N5   | (+)*       |
| MF protein Rx (g/day)  | NS | NS | NS    | (−)*         | (−)* | N5 | N5   | (−)*       | (−)*   | N5 | N5   | N5         |
| Plasma Phe (umoles/L) | (+)*** | (+)* | N5   | (+)***           | (+)*** | N5 | N5   | (+)**       | (+)**   | N5 | N5   | N5         |

* p < 0.05, ** p < 0.01, *** p < 0.001.

‡ Interaction defined as “variable*time*response category” in longitudinal mixed regression analysis.
† Results for Worries, Support, and Generally sub-scores not included since no significant changes occurred across time for these outcomes.
(+): indicates positive association, (−): indicates negative association, NS: not statistically significant.
D: Definitive Responders, N: Non-responders, P: Provisional Responders, All: Complete study sample.
Figure 4 (A and B): Mean (± 1 SD) Phe tolerance (mg/day) and prescribed medical food protein (g/day) of sapropterin response groups across study visits. Clustered bars represent study visits at Baseline, 1, 4, 8, and 12 months respectively. NS = Not significant.

Figure 5 Baseline dietary Phe compliance of patients with PKU. Dietary Phe compliance defined as patient-reported Phe intake in excess of Phe tolerance (PT) (mg/day). One patient with undetermined baseline Phe tolerance omitted from figure.
direction of Total, Impact, and Satisfaction scores. These beneficial outcomes were particularly evident in Definitive Responders. Of important distinction also is our use of a questionnaire tool specifically developed for measuring QOL in individuals with PKU. A lack of available QOL tools specific to inborn errors diagnoses was acknowledged by Ziesch as a possible limitation in his QOL study [22]. Although the PKU-QOLQ is still in the process of validation for males and other age groups, it proved highly effective at assessing QOL in our study sample, when controlling for age, with no observed gender differences in scoring outcomes. Internal consistency was considered good, with Cronbach Alpha > 0.8 for the questionnaire and its subsections, as well as across age and gender groups (Table 5). Hence, the differences in our study design, tools, and patient cohort offers the best explanation for the discrepancy between our study and Ziesch’s.

An interesting observation in this analysis was that differences in Phe tolerance were not associated with QOL outcomes at baseline, yet increased Phe tolerance over the course of one year in Definitive Responders was significantly associated with improved QOL outcomes. The lack of baseline association may be due to the psycho-emotional adaptation of these patients to the constraints of PKU diagnosis, as discussed earlier, particularly since patients have lived with the condition since birth. However, a fast dramatic increase in Phe tolerance that is sustained as a result of sapropterin treatment could boost QOL self-perception when measured over time. Whether that improvement in QOL can be sustained, or whether patients will habituate to their higher Phe tolerance with QOL gradually returning to baseline, remains to be seen in future analysis where follow-up extends beyond one year.

Also noteworthy is that Non-responders and Provisional Responders were without significant change to Phe tolerance or formula dependence, yet had significant improvement to their Impact QOL scores. The trend seen in Provisionals and Non-responders was modest compared to the improved QOL observed in Definitive Responders, but being statistically significant still deserves explanation. The modest QOL increase in these two groups may be due to a Hawthorne effect: essentially, the patients’ answers to QOL questions improved over time as a result of monitoring within the study parameters. Additionally, the QOL scores could reflect patient emotional benefit to increases in medical surveillance and monitoring, since all study subjects received more frequent personalized medical attention throughout the study year. A placebo effect in the case of Provisional Responders is also possible. Patients within this group anecdotally reported the benefit they felt sapropterin had on their lives even though their diets were not significantly liberalized. Therefore, patient self-reports of life benefits and improved emotional outcomes while on sapropterin should be considered objectively when these patients meet the criteria for provisional response [16]. If while on sapropterin patients are not benefitting from improved Phe control, nor demonstrating improved Phe tolerance, the clinical benefit of sapropterin in their PKU management plan should be scrutinized, particularly since impact on QOL would most likely be minimal.

Study results indicate baseline Support scores, in addition to other factors such as marital status and sapropterin response classification, could effectively predict long-term attrition within our PKU study cohort. In fact, sense of emotional support had the strongest relationship with study attrition, such that the amount of weeks spent in the study could be predicted by how high the support scores were at baseline, particularly in Non-responders where most of the attrition occurred. Interestingly, the Support section represents the smallest question cluster in the QOLQ. There are only 4 queries which ask about support received from the person’s family, friends, medical team, and nutrition team. An improvement in just one or two of these support aspects could dramatically reduce attrition risk in future studies, thus it may be worthwhile to ensure patients are provided an emotionally supportive clinical environment from their very first appointment when long term follow-up is indicated.

In agreement with other QOL studies, our analysis revealed an inverse association between age and QOL scores [26-28], thereby stressing the need to control for age when evaluating QOL differences in clinical groups, or to incorporate an age diversified QOL questionnaire.

### Table 5 Cronbach Alpha analysis of PKU QOL questionnaire

| Questionnaire Section | No. of questions | Overall alpha | Alpha for adults | Alpha for pediatrics | Alpha for males | Alpha for females |
|-----------------------|------------------|--------------|-----------------|---------------------|----------------|-------------------|
| Impact                | 18               | 0.87         | 0.84            | 0.89                | 0.89           | 0.85              |
| Worries               | 10               | 0.91         | 0.86            | 0.94                | 0.93           | 0.86              |
| Satisfaction          | 8                | 0.88         | 0.87            | 0.89                | 0.90           | 0.86              |
| Support               | 4                | 0.88         | 0.91            | 0.90                | 0.92           | 0.87              |
| General well-being    | 11               | 0.90         | 0.90            | 0.93                | 0.91           | 0.92              |
| Total questionnaire   | 51               | 0.95         | 0.94            | 0.96                | 0.96           | 0.94              |
system. Physical activity should also be controlled for when evaluating QOL, as our study indicated.

Due to several adult PKU study patients being neither employed nor in school, two work/school questions were frequently skipped. Modifications to the PKU-QOLQ may be necessary to accommodate this circumstance in adults, however for this study we resolved the issue by eliminating those two specific questions from final scoring and analyses.

Our study focused on patient self-reported QOL only; however, improved QOL outcomes may also occur in parents, caregivers, spouses, or other family members when an individual with PKU is able to increase dietary freedom due to a new treatment, such as sapropterin. Though our clinicians have received many positive anecdotal reports from family members and caregivers of sapropterin Responders (both Definitive and Provisional), a formal analysis is needed to determine measurable QOL benefits to these family members and caregivers. Such an analysis was beyond the scope of this investigation but would be a worthwhile pursuit for future study.

The present study results provide additional opportunity to assist patients with PKU in areas where they report feeling most challenged or discouraged from a social-medical perspective. The information gleaned can assist with technicalities of adjusting therapeutic protocols as patients gain access to emerging treatment options, such as sapropterin, which may offer more dietary freedom, as well as with planning of long term clinical studies. In this respect, patients can receive the emotional, medical, and nutritional support they need for effective lifelong management of their disorder.

Conclusion
Self-reported quality of life measured high on average in adolescents and adults with PKU. Nevertheless, marked improvements occurred in the QOL areas where impact on various aspects of life and self-sense of satisfaction were measured. Improvements were most dramatic for patients who experienced increased Phe tolerance while taking sapropterin. These improvements were accomplished while maintaining good Phe control in the majority of Definitive Responders. Non-responders and Provisionals, who had no increase in Phe tolerance, still demonstrated modest improvements to QOL during the study, albeit to a lesser extent than Definitive Responders. Aspects of general well being, sense of social support, and worries in relation to PKU and life were not associated with sapropterin response classification, Phe tolerance, medical food prescription, or PAA during the long-term study.

Competing interests
Independent Investigator sponsored trial with partial funding provided by BioMarin Pharmaceutical Inc.

Authors’ contributions
TDD was responsible for grant and protocol writing, adaptation of QOLQ for adult study population, distribution and collection of questionnaires, data entry, data management and analysis; statistical interpretation, and writing all parts of the manuscript including tables and graphs. UR made significant contributions in reviewing the article, advising analytical and statistical approaches as well as appropriate data management techniques, in recommending large scale revisions, and for providing additional project guidance and support. JAK provided crucial guidance regarding data collection, management, and analysis; and reviewed data results, provided feedback on statistical approaches, and assisted with reviewing and editing of the article drafts. RHS was the study Principle Investigator, provided management and supervision of grant writing, protocol development, patient dietetic management, data management, staff research activities, and data reporting; contributed to review and revising all manuscript drafts. All authors read and approved the final manuscript.

Acknowledgements
Supported in part by PHS Grant UL1 RR025008 from the Clinical and Translational Science Award program, National Institutes of Health, National Center for Research Resources. Special appreciation to the patients who participated in the study. Thanks to Mary Jane Kennedy (project coordinator), Sarah Travis (research dietician), Paul Fernhoff (MD), Muhammed Ali (MD) and additional faculty and staff within the Emory Genetics Clinic and Emory Genetics Laboratory. Thanks also to Phyllis Acosta, Kathryn Coakley, Sarah Yi and Meghan Quirk for their guidance and support, and to Emory statistician George Cotsonis for his guidance on statistical methods.

Author details
1Metabolic Nutrition Program, Division of Medical Genetics, Emory Department of Human Genetics, 2165 North Decatur Road, Decatur, GA 30033, USA. 2Nutrition and Health Sciences Program, Division of Biological and Biomedical Sciences, Laney Graduate School, Emory University, Atlanta, GA, USA. 3Hubert Department of Global Health, Emory University Rollins School of Public Health, 1518 Clifton Road NE. Room 7009, Atlanta, GA 30322, USA. 4Fetal Alcohol Syndrome and Drug Exposure Center, Marcus Autism Center, 1920 Briarcliff Road, Atlanta, GA 30324, USA. 5Division of Autism and Related Disorders, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA.

Received: 21 August 2013 Accepted: 20 December 2013
Published: 30 December 2013

References
1. Bilginsoy C, et al: Living with phenylketonuria: Perspectives of patients and their families. J Inherit Metab Dis 2005, 28:639-649.
2. Legge FF. Phenylketonuria—the lived experience. J New Zealand Med Assoc 2007, 120(2728).
3. Durham-Shearer SJ, Judd PA, Whelan K, Thomas JE: Knowledge, compliance and serum phenylalanine concentrations in adolescents and adults with phenylketonuria and the effect of a patient-focused educational resource. J Hum Nutr Diet 2008, 21:474–485.
4. Aoki K, Ohwada M, Kitagawa T: Long-term follow-up study of patients with phenylketonuria detected by the newborn screening programme in Japan. J Inherit Metab Dis 2007, 30:628–630.
5. Burton BK, et al: A diversified approach for PKU treatment: Routine screening yields high incidence of psychiatric distress in phenylketonuria clinics. Mol Genet Metab 2013, 108:8–12.
6. Arnold GL, et al: Prevalence of stimulant use for attentional dysfunction in children with phenylketonuria. J Inherit Metab Dis 2004, 27:137–143.
7. Weglage J, et al: Deficits in selective and sustained attention processes in early treated children with phenylketonuria—result of impaired frontal lobe functions? Eur J Pediatr 1996, 155:200–204.
8. Sharman R, Sullivan K, Young R, McGill J: Biochemical markers associated with executive function in adolescents with early and continuously treated phenylketonuria. Clin Genet 2009, 75:169–174.
9. Azadi B, et al. Executive dysfunction in treated phenylketonuric patients. 
Eur Child Adolesc Psychiatry 2009, 18:360–368.
10. Christ SE, et al: Inhibitory control in children with phenylketonuria. 
Dev Neuropsychol 2006, 30:845–864.
11. Steinerdrin BA, et al: Behaviour and school achievement in patients with 
early and continuously treated phenylketonuria. J Inherit Metab Dis 2000, 
23:548–562.
12. Simon E, et al: Evaluation of quality of life and description of the 
sociodemographic state in adolescent and young adult patients with 
phenylketonuria (PKU). Health Qual Life Outcomes 2008, 6:25.
13. Bik-Multanowski M, et al: Quality of life in noncompliant adults with 
phenylketonuria after resumption of the diet. J Inherit Metab Dis 2008, 
31(Suppl 2):S415–S419.
14. Gassio R, et al: Do adult patients with phenylketonuria improve their 
quality of life after introduction/resumption of a phenylalanine-restricted 
diet? Acta Paediatr 2003, 92:1474–1478.
15. Utz JR, et al: START, a double blind, placebo-controlled pharmacogenetic 
test of responsiveness to sapropterin dihydrochloride in phenylketonuria 
patients. Mol Genet Metab 2012, 105:193–197.
16. Singh RH, Quirk ME: Using change in plasma phenylalanine 
concentrations and ability to liberalize diet to classify responsiveness to 
tetrahydrobiopterin therapy in patients with phenylketonuria. Mol Genet 
Metab 2011, 104:485–491.
17. Ingersoll M: A modified quality-of-life measure for youths: psychometric 
properties. Diabetes Educ 1991, 17:114–118.
18. Singh RH, et al: Impact of a Camp Experience on Phenylalanine Levels, 
Knowledge, Attitudes, and Health Beliefs Relevant to Nutrition 
Management of Phenylketonuria in Adolescent Girls. J Am Diet Assoc 2000, 100:797–808.
19. Cohen J, Cohen P, West SG, Aiken LS. Statistical Power Analysis for the Behavioral 
Sciences. 2nd edition. Hillsdale, NJ: Lawrence Earlbaum Associates; 1988.
20. RH Heck SLT, Tabata LN, Heck RH SLT, Tabata LN: Multilevel and 
longitudinal modeling with IBM SPSS. In G.A. Marcoulides. 1st edition. 
Edited by Quantitative Methodology Series. New York: Routledge; 2010:343.
21. Cotugno G, et al: Adherence to diet and quality of life in patients with 
phenylketonuria. Acta Paediatr 2011, 100:1144–1149.
22. Ziesch B, et al: Tetrahydrobiopterin (BH(4)) in PKU: effect on dietary 
treatment, metabolic control, and quality of life. J Inherit Metab Dis 2012, 
35:983–992.
23. Bosch AM, et al: Remarkable differences: the course of life of young 
adults with galactosaemia and PKU. J Inherit Metab Dis 2009, 32:706–712.
24. Landolt MA, et al: Quality of life and psychologic adjustment in children 
and adolescents with early treated phenylketonuria can be normal. 
J Pediatr 2002, 140:516–521.
25. Gourin CG: Quality of life is more than the sum of its parts. Otolaryngol 
Head Neck Surg 2008, 139:273–274.
26. Fryback DG, et al: US norms for six generic health-related quality-of-life 
indexes from the National Health Measurement study. Med Care 2007, 
45:1162–1170.
27. Hammer I, et al: Report of nationally representative values for the 
noninstitutionalized US adult population for 7 health-related quality-of-life 
scores. Med Decis Making 2006, 26:391–400.
28. Wagner VM, et al: Age, metabolic control and type of insulin regime 
influences health-related quality of life in children and adolescents with 
type 1 diabetes mellitus. Eur J Pediatr 2005, 164:491–496.